New drug TAK-360 tested for Long-Term safety in sleep disorders

NCT ID NCT07646678

Recruiting now Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 6 times

Summary

This study looks at the long-term safety and tolerability of the drug TAK-360 in people with narcolepsy (type 1 or 2) or idiopathic hypersomnia — conditions that cause severe daytime sleepiness. Participants who completed a previous TAK-360 study can join and will continue taking the drug. The main goal is to see how well people tolerate TAK-360 over many months and to track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAK-360
What this could lead to: If successful, this could confirm that TAK-360 is safe enough to use long-term for managing excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia.
What could go wrong: This is an extension study focused on safety, not on proving how well the drug works. It may not show clear benefits, and side effects could emerge over longer use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC HYPERSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic hypersomnia narcolepsy without cataplexy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC HYPERSOMNIA NARCOLEPSY TYPE 1 NARCOLEPSY TYPE 2

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Takeda Site 1
RECRUITING

Shinjuku-ku, Tokyo, 162-0851, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.